Syphilis Risk May Be Higher in HIV Patients on Antiretrovirals

Share this content:
Syphilis Risk May Be Higher in HIV Patients on Antiretrovirals
Syphilis Risk May Be Higher in HIV Patients on Antiretrovirals

TUESDAY, Jan. 17, 2017 (HealthDay News) -- Men who have sex with men (MSM) receiving antiretroviral therapy (ART) to treat HIV infection may be at increased risk for syphilis, according to research published online Jan. 16 in Sexually Transmitted Infections.

Based on a review of available evidence, Michael Rekart, M.D., from the University of British Columbia's School of Population and Public Health in Vancouver, Canada, and colleagues concluded that the drugs may boost susceptibility to the bacterium that causes syphilis, although the study did not prove cause-and-effect. The finding might explain why new and repeat cases of syphilis in MSM have risen sharply compared to other sexually transmitted infections (STIs) over the past decade, the researchers suggest.

The authors of an editorial that accompanied the study said the theory is "intriguing" and "warrants careful consideration." But the editorial also suggested that the increase in syphilis cases among MSM may be due to other factors. "We are living in an era where ART is being used to effectively treat and prevent HIV infection. To some extent, this seems to have tempered the urgency to control other STIs. As history has shown many times over, that would be a costly mistake," Susan Tuddenham, M.D., and colleagues from the Johns Hopkins University School of Medicine in Baltimore write.

"If further investigations support a role for ART in increasing susceptibility to syphilis, this will provide one more reason why screening, diagnosis, and treatment of STIs in MSM must be prioritized," the editorial authors conclude.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths